14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:CFRX
Delisted

ContraFect Corporation Stock Price (Quote)

NASDAQ Stock Exchange > Healthcare > Biotechnology
Open Broker Account
$0.0500
+0 (+0%)
At Close: Mar 04, 2024
Forecast Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $0.0500 $0.0500 Monday, 4th Mar 2024 CFRX stock ended at $0.0500. During the day the stock fluctuated 0% from a day low at $0.0500 to a day high of $0.0500.
90 days $0.0457 $0.0620
52 weeks $0.0430 $3.95

Historical ContraFect Corporation prices

Date Open High Low Close Volume
Jan 26, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 25, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 24, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 23, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 22, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 19, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 18, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 17, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 16, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 12, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 11, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 10, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 09, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 08, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 05, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 04, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 03, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Jan 02, 2024 $0.0500 $0.0500 $0.0500 $0.0500 0
Dec 29, 2023 $0.0500 $0.0500 $0.0500 $0.0500 0
Dec 28, 2023 $0.0500 $0.0500 $0.0500 $0.0500 0
Dec 27, 2023 $0.0500 $0.0500 $0.0500 $0.0500 0
Dec 26, 2023 $0.0500 $0.0500 $0.0500 $0.0500 0
Dec 22, 2023 $0.0500 $0.0500 $0.0500 $0.0500 0
Dec 21, 2023 $0.0500 $0.0500 $0.0500 $0.0500 0
Dec 20, 2023 $0.0500 $0.0500 $0.0500 $0.0500 0
Click to get the best stock tips daily for free!

About ContraFect Corporation

ContraFect ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the in... CFRX Profile

Golden Star

Ticker Date Change Price
MLI Apr 19 10.86% $52.28
LPLA Apr 19 0.743% $262.59
DOOR Apr 18 0.160% $131.39
LNG Apr 17 0.389% $156.81
FCN Apr 16 2.95% $207.62
ELV Apr 16 5.28% $506.97
DXC Apr 08 0.767% $20.87
AKR Apr 05 5.63% $16.53
ITCI Apr 05 6.84% $68.44
SARK Mar 28 13.80% $26.88
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT